Abstract:e13508 Background: Murine double minute-2 (MDM2) has increasing clinic relevance as preclinical and early clinical evidences have showed that the MDM2 inhibitors are promising alternative treatments for patients with MDM2-amplified (-amp) and TP53-wild-type (-WT) tumors by preventing TP53 protein degradation. However, exploration into genomic landscape of MDM2/TP53 across various solid tumors in Chinese patients is still limited. Methods: Formalin-fixed, paraffin-embedded (FFPE) tumor samples were collected from 10010 Chinese patients with solid tumors and subjected to a clinical-grade next-generation sequencing (NGS)-based 450 gene panel testing carried out by a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. Genomic alterations (GAs) including single base substitutions, short and long insertion/deletions (Indels), copy number variations, gene fusions, and rearrangements were analyzed. Tumor mutational burden (TMB) was measured by a NGS algorithm. Results: Amplification of MDM2 occurred in 3.3% of Chinese patients. MDM2-amp was detected most frequently in soft tissue sarcoma (STS, 11.4 %), melanoma (10.3 %) and osteosarcoma (6.3 %). Notably, MDM2-amp was revealed to be mutually exclusive with TP53-mut in most tumor types other than esophageal carcinoma (93.9 %), head and neck carcinoma (68.4%) and ovarian carcinoma (50 %). Tumors with highest frequencies of MDM2-amp/ TP53-WT were melanoma (100%), osteosarcoma (100%) and urothelial carcinoma (100 %). The most common co-altered genes accompanied with MDM2-amp were FRS2 (84%), CDK4 (38%), EGFR (26%), TP53 (17%) and GLI1 (14%). 82.8% patients who had one or more co-alterations potentially targetable with either FDA-approved or investigational agent. Moreover, TMB of MDM2-amp tumors were significantly lower than that of MDM2-WT and MDM2-mutation (-mut) tumors (median TMB: 3.1 vs. 4.6 vs. 10.8, p < 0.001 respectively). Conclusions: MDM2 amplification was found in 3.3% of 10010 Chinese cancer patients, 83.4% of whom harbored wild-type TP53 that were potentially responsive to MDM2 inhibitors. In addition, 82.8% of the patients with MDM2-amp harbored genomic co-alterations and were potentially therapy targetable. This study provided insights into identifying patients who might potentially benefit from anti-MDM2 therapies.

Supplementary Table S5 from Two Types of Human Malignant Melanoma Cell Lines Revealed by Expression Patterns of Mitochondrial and Survival-Apoptosis Genes: Implications for Malignant Melanoma Therapy

Supplementary Table S3 from Two Types of Human Malignant Melanoma Cell Lines Revealed by Expression Patterns of Mitochondrial and Survival-Apoptosis Genes: Implications for Malignant Melanoma Therapy

Supplementary Fig. S2 from Two Types of Human Malignant Melanoma Cell Lines Revealed by Expression Patterns of Mitochondrial and Survival-Apoptosis Genes: Implications for Malignant Melanoma Therapy

Two Types of Human Malignant Melanoma Cell Lines Revealed by Expression Patterns of Mitochondrial and Survival-Apoptosis Genes: Implications for Malignant Melanoma Therapy

Supplementary Tables 1 - 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Table S1-S5 from Skp2-Mediated Stabilization of MTH1 Promotes Survival of Melanoma Cells Upon Oxidative Stress

Supplementary Table 2 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Table 1 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Table S6 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure S2 from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Table 14 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance

Supplementary Table 3 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Table S6 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations

Comprehensive Profiling of MDM2/TP53 Genomic Aberration in Chinese Patients with Diverse Malignancies.

Supplementary Tables 1-2, Figures 1-2 from Distinctive MicroRNA Profiles Relating to Patient Survival in Esophageal Squamous Cell Carcinoma

Healthy Mitochondria: The Brake of Cell Proliferation of Malignant Melanoma

Mitochondrial Metabolism in Melanoma

Supplementary Data from Mitochondrial Mirna Determines Chemoresistance by Reprogramming Metabolism and Regulating Mitochondrial Transcription

Table S1 from Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications

Supplementary Table from Atezolizumab Plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

Supplementary Data 2 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death